April 19, 2023 Gamida Cell Announces Pricing of $23 Million Public Offering of Securities View Article
April 18, 2023 Clinical data validate pioneering MeMed BV technology improves diagnosis of pediatric patients with fever in the Emergency Department View Article
April 3, 2023 Alpha Tau and the JGH Announce Alpha DaRT Treatment of First Patient in its Advanced Pancreatic Cancer Clinical Trial View Article
March 31, 2023 PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds View Article
March 8, 2023 Alpha Tau Announces Alpha DaRT™ Treatment of First Two Patients in its Pivotal Multicenter Recurrent Skin Cancer (ReSTART) Trial View Article
March 3, 2023 Alpha Tau Announces Grant of Expanded Radioactive License and Final Pre-Clinical Laboratory Regulatory Approval at its Jerusalem Headquarters View Article
March 1, 2023 Alpha Tau Announces Health Canada Authorization for Alpha DaRT Clinical Trial for the Treatment of Liver Metastases View Article
